Merger and Acquisition Scenario

Summary

Other Scenarios:

AMLN - PG
AMLN - JNJ
PG - ARXT
JNJ - ARXT

Buyer:	Amylin Pharmaceuticals, Inc. (AMLN)	Last Price:	32.46	Market Cap.:	4.38B
Target:	Adams Respiratory Therapeutics, Inc. (ARXT)	Last Price:	59.99	Market Cap.:	2.16B

Lines of Business Summary:

Amylin Pharmaceuticals, Inc. (AMLN) competes in 1 industry and 5 product/service groups
Adams Respiratory Therapeutics, Inc. (ARXT) competes in 1 industry and 5 product/service groups
A combined entity will have 0% Product/Service Group overlap
Amylin Pharmaceuticals, Inc. (AMLN) has 1 and Adams Respiratory Therapeutics, Inc. (ARXT) has 0 suppliers that rely on a material % of their business. They share 0 in common.
Amylin Pharmaceuticals, Inc. (AMLN) has 0 and Adams Respiratory Therapeutics, Inc. (ARXT) has 3 customers that derive significant revenue from each. They share 0 in common.

Product Summary:

Overlap & Complementary Sectors

Sector	Buyer	Target	# of Focused Companies
Healthcare			927
Biopharmaceuticals			379

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

Sample Products in Similar Lines of Business	Sample Products in Complementary Lines of Business
Buyer (Total: 7) Symlin (Pramlintide Acetate) Byetta (Exenatide) Exenatide LAR ( Long-Acting Release Exendin-4) Nasal Exenatide (Incretin Mimetic)	Target (Total: 9) Erdosteine Delsym Orange/Delsym Grape (Dextromethorphan Polistirex) Mucinex DM (Guaifenesin/Dextromethorphan Hydrobromide Extended Release) Maximum Strength DM (Guaifenesin/Dextromethorphan Hydrobromide Extended Release)	Buyer n/a	Target n/a

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business

Buyer (Total: 7)

Symlin (Pramlintide Acetate)
Byetta (Exenatide)
Exenatide LAR ( Long-Acting Release Exendin-4)
Nasal Exenatide (Incretin Mimetic)

Target (Total: 9)

Erdosteine
Delsym Orange/Delsym Grape (Dextromethorphan Polistirex)
Mucinex DM (Guaifenesin/Dextromethorphan Hydrobromide Extended Release)
Maximum Strength DM (Guaifenesin/Dextromethorphan Hydrobromide Extended Release)

Buyer

n/a

Target

n/a

Business Relationship Summary:

Top Key Suppliers	Top Key Customers
Buyer (Total: 9) Alexandria Real Estate Equities, Inc. (ARE) GlaxoSmithKline plc (ADR) (GSK) Baxter International Inc. (BAX) Covidien Ltd. (COV)	Target (Total: 4) Cardinal Health, Inc. (CAH) UCB S.A. MonoSol, LLC Boehringer Ingelheim GmbH	Buyer (Total: 1) Eli Lilly & Co. (LLY)	Target (Total: 12) Wal-Mart Stores, Inc. (WMT) CVS Caremark Corporation (CVS) Walgreen Company (WAG) Target Corporation (TGT)

Top Key Suppliers

Top Key Customers

Buyer (Total: 9)

Alexandria Real Estate Equities, Inc. (ARE)
GlaxoSmithKline plc (ADR) (GSK)
Baxter International Inc. (BAX)
Covidien Ltd. (COV)

Target (Total: 4)

Cardinal Health, Inc. (CAH)
UCB S.A.
MonoSol, LLC
Boehringer Ingelheim GmbH

Buyer (Total: 1)

Eli Lilly & Co. (LLY)

Target (Total: 12)

Wal-Mart Stores, Inc. (WMT)
CVS Caremark Corporation (CVS)
Walgreen Company (WAG)
Target Corporation (TGT)

Key Financial Summary:

Key Metrics

	Buyer	Target
Number of Employees	1,550	463
Revenue Per Employee	491,742.1	952,726.8
Total Revenue	190.0	110.0
Total Expenses	238.0	63.8
Other Revenue	0.0	0.0
Cost of Revenue	13.8	28.5
SG&A Expense	87.7	29.9
Research & Development	61.5	6.3
Other Operating Expense	75.0	0.0
Operating Income	-47.9	46.2
Unusual Income	0.0	0.0
LT Debt to Capital	56.77	0
Fwd P/E	-22.82	34.69
Fwd P/Rev	5.88	5.08
Book Value	612.4	307.1
Curr Portion of LTD/Cap Lease	0.0	0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Endocrinology/Metabolism > Diabetes

Target

Focused (): Healthcare > Biopharmaceuticals > Respiratory System > Upper Respiratory Tract Disorders > Coughs/Colds

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for the treatment of diabetes, obesity and other diseases. The Company has developed and gained approval for two products: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company has ongoing programs in pharmaceutical discovery and development, including late-stage programs for diabetes and obesity. The Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop a sustained-release formulation of exenatide, which it refers to as Exenatide LAR, to enable once-weekly administration of exenatide for the treatment of type 2 diabetes. It has four ongoing clinical trials designed to evaluate compounds as new treatments for obesity.

Target

Adams Respiratory Therapeutics, Inc., is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter (OTC), and prescription pharmaceuticals for the treatment of respiratory disorders. The Company markets market six oral-solid OTC products for adults under its Mucinex brand, six products in its Mucinex line of products for children, two Mucinex nasal spray products, and two products under its Delsym brand. In July 2007, the Company expanded the Mucinex franchise with its first nasal spray product, Mucinex Full Force Nasal Spray. In August 2007, it also began to market a second nasal spray product, Mucinex Moisture Smart Nasal Spray.

Deal Summary

Key Ratios

	Buyer	Target
Gross Margin %	92.46	72.99
Operating Margin %	-31.2	19.45
Quick Ratio	4.98	2.77
Current Ratio	5.57	4.26
Coverage Ratio	0.04	0
Total Assets	1,650.7	361.2
Return on Equity %	-31.45	14.19
Return on Assets %	-11.67	12.07
Cash+ ST Inv. Per Share	8.15	1.79
Total Debt	804.1	0.0
Total Debt to Equity %	131.3	0
Total Debt to Tangible Equity %	131.3	0
Debt to Asset %	48.71	0.00

Product Summary

Sector

Buyer

Target

Healthcare

Biopharmaceuticals

Endocrinology/Metabolism

The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.

Respiratory System

The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.

Weight Management

The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector

Buyer

Target

Healthcare

Biopharmaceuticals

Endocrinology/Metabolism

Diabetes

Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes

Insulin Therapy

Adjunctive

Therapeutics that treat Insulin Dependent Diabetes Mellitus by insulin or insulin-like supplements.

Buyer Products:

Symlin (Pramlintide Acetate)

Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)

Therapeutics that treat non-insulin dependent diabetes by stimulating the Glucagon-Like Peptide (GLP) receptor. GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.

Buyer Products:

Byetta (Exenatide)
Exenatide LAR ( Long-Acting Release Exendin-4)

Insulin Therapy

Adjunctive

Therapeutics that aids in, but not essential, to insulin therapy for the treatment of diabetes.

Buyer Products:

Symlin (Pramlintide Acetate)

Phase I/Phase II Clinical Stage Products

Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

Nasal Exenatide (Incretin Mimetic)

Respiratory System

Phase I/Phase II Clinical Stage Products

Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Target Products:

Erdosteine

Upper Respiratory Tract Disorders

Coughs/Colds

Antitussives

Therapeutics that relieve or prevent coughs.

Target Products:

Delsym Orange/Delsym Grape (Dextromethorphan Polistirex)

Antitussives/Expectorants

Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.

Target Products:

Mucinex DM (Guaifenesin/Dextromethorphan Hydrobromide Extended Release)
Maximum Strength DM (Guaifenesin/Dextromethorphan Hydrobromide Extended Release)

Decongestants/Expectorants

Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.

Target Products:

Mucinex D (Guaifenesin/Pseudoephedrine HCl Extended Release)
Maximum Strength D (Guaifenesin/Pseudoephedrine HCl Extended Release)

Expectorants

Therapeutics that treat coughs and colds by helping in the ejection of mucous.

Target Products:

Mucinex SE (Guaifenesin Extended Release)
Humibid SE (Guaifenesin Extended Release)
Mucinex With Codeine (Guaifenesin/Codeine Combination Extended-Release)

Weight Management

Phase I/Phase II Clinical Stage Products

Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

Second-Generation Amylinomimetic
PYY 3-36
Pramlintide

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

	Name	Percent	Market Cap.	P/E Ratio (TTM)	Fwd P/E	P/R Ratio (TTM)	Fwd P/Rev	Price To Tang. Book Value
Overlap
	Novartis AG (ADR)	n/a	115,310.846	13.94	14.29	3.03	2.95	4.04
Buyer
	Pfizer Inc.	n/a	154,421.887	18.62	9.64	3.18	3.31	n/a
	Roche Holding Ltd. (ADR)	n/a	152,328.536	19.21	18.12	3.77	3.89	5.64
	GlaxoSmithKline plc (ADR)	n/a	129,213.735	12.21	12.17	2.87	2.89	12.60
	Novartis AG (ADR)	n/a	115,310.846	13.94	14.29	3.03	2.95	4.04
	sanofi-aventis (ADR)	n/a	109,679.174	18.58	11.12	2.51	2.86	n/a
	Merck & Co., Inc.	n/a	104,018.133	19.33	15.78	4.33	4.44	5.62
	Abbott Laboratories	n/a	85,731.688	71.26	17.72	11.87	3.15	n/a
	AstraZeneca plc (ADR)	n/a	62,499.553	10.85	10.83	2.19	2.20	n/a
	Eli Lilly & Co.	n/a	57,555.042	25.80	14.54	3.25	3.18	5.48
	Bristol Myers Squibb Co.	n/a	45,446.398	21.44	15.99	2.43	2.34	9.69
	Novo Nordisk A/S (ADR)	n/a	39,545.627	21.35	21.73	4.78	4.91	6.10
	MannKind Corporation	n/a	733.667	0.00	-1.90	99,589.04	124.42	4.08
Target
	The Procter & Gamble Company	n/a	202,829.283	19.14	19.01	2.60	2.51	n/a
	Johnson & Johnson	n/a	178,744.902	16.90	14.37	2.93	2.86	n/a
	Novartis AG (ADR)	n/a	115,310.846	13.94	14.29	3.03	2.95	4.04
	Bayer AG (ADR)	n/a	60,061.987	8.29	15.86	1.31	1.43	n/a
	Wyeth	n/a	54,717.260	12.29	12.14	2.50	2.58	4.38
	CVS Caremark Corporation	n/a	52,518.244	23.60	18.95	0.79	0.70	n/a
	Walgreen Company	n/a	33,984.520	16.46	15.98	0.62	0.58	3.26
	Schering-Plough Corporation	n/a	30,807.112	15.76	14.94	2.65	2.70	2.35
	Rite Aid Corporation	n/a	1,805.396	0.00	-8.24	0.08	0.08	n/a
	Matrixx Initiatives, Inc.	n/a	137.966	20.92	16.04	1.49	1.41	2.75
	MiddleBrook Pharmaceuticals, Inc.	n/a	128.504	0.00	-3.36	14.53	9.94	n/a
	Airborne, Inc.	n/a	n/a	n/a	n/a	n/a	n/a	n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

	Name	Dir	Percent	Market Cap.	P/E Ratio (TTM)	Fwd P/E	P/R Ratio (TTM)	Fwd P/Rev	Price To Tang. Book Value
Buyer
	Alexandria Real Estate Equities, Inc.		1.90%	3,157.509	43.17	17.50	8.08	n/a	2.12
GlaxoSmithKline plc (ADR)		n/a	129,213.735	12.21	12.17	2.87	2.89	12.60
Baxter International Inc.		n/a	38,678.422	22.66	19.82	3.43	3.31	5.59
Covidien Ltd.		n/a	21,193.089	0.00	16.82	2.08	2.04	n/a
Alkermes, Inc.		n/a	1,391.017	60.81	98.29	5.46	5.63	5.83
Nastech Pharmaceutical Co. Inc.		n/a	66.591	0.00	-1.23	4.02	4.08	1.34
Bachem AG		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Lonza Group Ltd.		n/a	n/a	n/a	n/a	n/a	n/a	n/a
CP Pharmaceuticals Limited		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Target
	Cardinal Health, Inc.		n/a	20,399.391	10.40	14.32	0.23	0.22	16.38
UCB S.A.		n/a	n/a	n/a	n/a	n/a	n/a	n/a
MonoSol, LLC		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Boehringer Ingelheim GmbH		n/a	n/a	n/a	n/a	n/a	n/a	n/a

Name

Dir

Percent

Market Cap.

P/E Ratio (TTM)

Fwd P/E

P/R Ratio (TTM)

Fwd P/Rev

Price To Tang. Book Value

Buyer

Alexandria Real Estate Equities, Inc.

1.90%

3,157.509

43.17

17.50

8.08

n/a

2.12

GlaxoSmithKline plc (ADR)

n/a

129,213.735

12.21

12.17

2.87

2.89

12.60

Baxter International Inc.

n/a

38,678.422

22.66

19.82

3.43

3.31

5.59

Covidien Ltd.

n/a

21,193.089

0.00

16.82

2.08

2.04

n/a

Alkermes, Inc.

n/a

1,391.017

60.81

98.29

5.46

5.63

5.83

Nastech Pharmaceutical Co. Inc.

n/a

66.591

0.00

-1.23

4.02

4.08

1.34

Bachem AG

n/a

Lonza Group Ltd.

n/a

CP Pharmaceuticals Limited

n/a

Target

Cardinal Health, Inc.

n/a

20,399.391

10.40

14.32

0.23

0.22

16.38

UCB S.A.

n/a

MonoSol, LLC

n/a

Boehringer Ingelheim GmbH

n/a

- Defined by the Company - Defined by Others

Key Customers

	Name	Percent	Market Cap.	P/E Ratio (TTM)	Fwd P/E	P/R Ratio (TTM)	Fwd P/Rev	Price To Tang. Book Value
Buyer
	Eli Lilly & Co.	n/a	57,555.042	25.80	14.54	3.25	3.18	5.48
Target
	Wal-Mart Stores, Inc.	10.00%	192,591.266	15.32	15.73	0.52	0.52	4.00
	CVS Caremark Corporation	10.00%	52,518.244	23.60	18.95	0.79	0.70	n/a
	Walgreen Company	10.00%	33,984.520	16.46	15.98	0.62	0.58	3.26
	Target Corporation	n/a	42,871.603	14.59	15.68	0.68	0.69	2.65
	Cardinal Health, Inc.	n/a	20,399.391	10.40	14.32	0.23	0.22	16.38
	Publix Super Markets (OLD)	n/a	19,117.951	23.33	n/a	1.02	n/a	5.33
	McKesson Corporation	n/a	17,478.994	17.80	18.69	0.18	0.18	5.56
	The Kroger Co.	n/a	17,090.806	13.74	15.26	0.24	0.25	6.52
	Safeway Inc.	n/a	13,754.216	15.36	15.85	0.33	0.33	3.37
	Sears Holdings Corporation	n/a	13,626.014	11.22	18.42	0.26	0.28	2.41
	AmerisourceBergen Corp.	n/a	7,329.741	16.05	16.00	0.11	0.11	2.54
	Rite Aid Corporation	n/a	1,805.396	0.00	-8.24	0.08	0.08	n/a

- Defined by the Company - Defined by Others

Key Partners

	Name	Percent	Market Cap.	P/E Ratio (TTM)	Fwd P/E	P/R Ratio (TTM)	Fwd P/Rev	Price To Tang. Book Value
Buyer
	GlaxoSmithKline plc (ADR)	n/a	129,213.735	12.21	12.17	2.87	2.89	12.60
	Eli Lilly & Co.	n/a	57,555.042	25.80	14.54	3.25	3.18	5.48
	Amgen, Inc.	n/a	52,328.182	16.53	11.01	3.54	3.46	15.87
	Baxter International Inc.	n/a	38,678.422	22.66	19.82	3.43	3.31	5.59
	Covidien Ltd.	n/a	21,193.089	0.00	16.82	2.08	2.04	n/a
	Inverness Medical Innovations, Inc.	n/a	3,093.221	0.00	50.60	4.37	3.84	n/a
	Alkermes, Inc.	n/a	1,391.017	60.81	98.29	5.46	5.63	5.83
	Nastech Pharmaceutical Co. Inc.	n/a	66.591	0.00	-1.23	4.02	4.08	1.34
	Bachem AG	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Target
	Wal-Mart Stores, Inc.	n/a	192,591.266	15.32	15.73	0.52	0.52	4.00
	CVS Caremark Corporation	n/a	52,518.244	23.60	18.95	0.79	0.70	n/a
	Target Corporation	n/a	42,871.603	14.59	15.68	0.68	0.69	2.65
	Walgreen Company	n/a	33,984.520	16.46	15.98	0.62	0.58	3.26
	Cardinal Health, Inc.	n/a	20,399.391	10.40	14.32	0.23	0.22	16.38
	Publix Super Markets (OLD)	n/a	19,117.951	23.33	n/a	1.02	n/a	5.33
	McKesson Corporation	n/a	17,478.994	17.80	18.69	0.18	0.18	5.56
	The Kroger Co.	n/a	17,090.806	13.74	15.26	0.24	0.25	6.52
	Safeway Inc.	n/a	13,754.216	15.36	15.85	0.33	0.33	3.37
	Sears Holdings Corporation	n/a	13,626.014	11.22	18.42	0.26	0.28	2.41
	AmerisourceBergen Corp.	n/a	7,329.741	16.05	16.00	0.11	0.11	2.54
	Rite Aid Corporation	n/a	1,805.396	0.00	-8.24	0.08	0.08	n/a
	Lipocine Inc.	n/a	n/a	n/a	n/a	n/a	n/a	n/a
	Boehringer Ingelheim GmbH	n/a	n/a	n/a	n/a	n/a	n/a	n/a
	UCB S.A.	n/a	n/a	n/a	n/a	n/a	n/a	n/a
	MonoSol, LLC	n/a	n/a	n/a	n/a	n/a	n/a	n/a

- Defined by the Company - Defined by Others

Financials

	Buyer	Target	Combined Entity
Income Statement
Operating Items
Revenue	722.3	351.4	1,073.8
Other Revenue	0.0	0.0	0.0
Total Revenue	722.3	351.4	1,073.8
Cost of Revenue	54.5	94.9	149.4
SG&A Expense	358.2	162.8	520.9
Depreciation & Amortization	0.0	0.0	0.0
Research & Development	258.9	23.8	282.7
Interest Expense	0.0	-1.1	-1.1
Other Operating Expense	276.1	2.7	278.8
Total Expenses	947.7	283.1	1,230.7
Operating Income	-225.3	68.4	-157.0
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng	-9.7	0.0	-9.7
Other, Net	42.5	0.0	42.5
Income Before Taxes	-192.6	68.4	-124.3
Income Taxes	0.0	24.8	24.8
Income After Taxes	-192.6	43.6	-149.0
Net Income - Excl. Xord. Items	-192.6	43.6	-149.0
Net Income - Incl. Xord. Items	-192.6	43.6	-149.0
Income Avail. to Common	-192.6	43.6	-149.0
Share Items
Basic Avg. Shares Outstanding	132.8	35.8	168.6
Basic EPS - Excl. Xord. Items	n/a	1.22	-0.88
Basic EPS - Incl. Xord. Items	n/a	1.22	-0.88
Full Dilution Adjustment	0.0	0.0	0.0
Fully Diluted Shares Outstanding	132.8	37.2	170.0
F.D. EPS - Excl. Xord. Items	n/a	1.17	-0.88
F.D. EPS - Incl. Xord. Items	n/a	1.17	-0.88
Balance Sheet
Assets
Cash and Equivalents	337.3	32.8	370.1
ST Investments	745.1	33.7	778.8
Accounts Receivable	63.2	67.4	130.6
Inventory	103.5	55.9	159.4
Prepayments and Advances	0.0	7.9	7.9
Other Current Assets	32.2	8.1	40.3
Current Assets	1,281.3	205.8	1,487.1
PPE	0.0	24.6	24.6
Accum D&A	0.0	-4.2	-4.2
PPE, Net	335.6	20.4	356.0
Goodwill & Intangibles	0.0	125.4	125.4
Other Assets	0.0	0.0	0.0
Other LT Assets	33.8	9.7	43.5
Total Assets	1,650.7	361.2	2,011.9
Liabilities
Accounts Payable	100.0	0.0	100.0
Payable/Accrued	0.0	19.1	19.1
Accrued Expenses	89.4	11.6	101.0
ST Debt	0.0	0.0	0.0
Other (Current) Liabilities	40.6	17.5	58.2
Current Liab.	230.0	48.3	278.3
LT Debt	804.1	0.0	804.1
Total LT Debt	804.1	0.0	804.1
Deferred Taxes	0.0	2.9	2.9
Other LT Liab.	4.2	2.9	7.1
Total Liabilities	1,038.3	54.1	1,092.4
Shareholders Equity
Common Stock	0.1	0.4	0.5
Additional Paid in Capital	1,968.9	492.2	2,461.1
Retained Earnings	-1,357.4	-185.4	-1,542.8
Other Equity	0.8	-0.0	0.8
Total Equity	612.4	307.1	919.6
Total Liab. & Equity	1,650.7	361.2	2,011.9
Shares Outstanding	134.7	35.9	170.6
Cash Flow
Operating Cash Flow
CF Net Income	-192.6	43.6	-149.0
CF Depreciation	19.9	4.7	24.6
CF Deferred Taxes	0.0	-6.9	-6.9
Other Non-Cash Items	66.3	10.9	77.2
Change in Working Capital	-5.3	-38.7	-44.0
Total Cash From Operating Activities	-111.8	13.6	-98.2
Investing Cash Flow (not calculated)
Capital Expenditures	-261.8	-8.7	-270.5
Other Investing Cash Flows	-67.6	2.9	-64.6
Total Cash From Investing Activities	-329.3	-5.8	-335.1
Financing Cash Flow (not calculated)
Dividends Paid	0.0	0.0	0.0
Purchase Or Sale of Stock	66.2	2.6	68.9
Purchase and Retirement of Debt	558.7	-10.2	548.5
Other Financing Cash Flow	0.0	8.4	8.4
Total Cash From Financing Activities	624.9	0.8	625.8
Exchange Rate Effects	0.0	0.0	0.0
Net Change in Cash	183.8	8.6	192.5
Cash Taxes Paid	0.0	15.9	15.9
Cash Interest Paid	6.4	0.3	6.7